Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...

阿尔茨海默症其新药研发失败率高达99.6%。昨天我们分享了两家失败的药物Simufilam和AL002，其 针对的靶点较为新颖。今日我们就其靶点和数据进行分析。

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

在生物制药板块面临挑战的背景下，Cassava Sciences Inc. (SAVA)的股价已跌至52周低点，触及3.35美元。根据 InvestingPro 的数据，该公司保持着3.55的健康流动比率，且现金多于债务，尽管技术指标显示该股票目前处于超卖状态。作为神经退行性疾病药物研发的前沿公司，Cassava Sciences的股票受到了更广泛的市场逆风和对其管线进展的特定担忧的打击。过去一年 ...

智通财经APP获悉，周一，Cassava Sciences(SAVA.US)股价暴跌，截至发稿，该股跌超84%，报4.06美元。该公司表示，其simufilam治疗轻度至中度阿尔茨海默症的3期ReThink-ALZ研究的初步结果没有达到预先设定的共同主要终点、次要终点和探索性生物标志物终点。 该公司总裁兼首席执行官里克·巴里表示：“对于患有这种疾病的患者及其家属以及一直在寻找新治疗方案的医生来说， ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

周一，Cassava Sciences经历了市场情绪的重大转变，Rodman & Renshaw将该公司股票评级从买入下调至卖出，目标价从之前的107.00美元大幅调整至2.00美元。此次降级紧随Cassava宣布其针对阿尔茨海默病潜在治疗药物simufilam的3期ReThink-ALZ研究未能达到关键终点。

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

Cassava Sciences (NASDAQ:SAVA) stock has plummeted ~86% after announcing that Alzheimer's disease candidate simufilam did ...